

PRESS RELEASE

April 26, 2025

Rottapharm Biotech presents recent results on CR10049, the first OA-targeted kinase inhibitor for the treatment of the inflammatory osteoarthritis (OA) phenotype, at the OARSI World Congress on OA

Monza (Italy) – Rottapharm Biotech, a research company dedicated to the discovery and development of innovative drugs, today announces that new exciting preclinical data supporting the advancement of CR10049 (a targeted kinase inhibitor for the inflammatory OA phenotype) have been presented at the Osteoarthritis Research Society International (OARSI) World Congress on Osteoarthritis, held April 24 – 27, 2025 in Incheon, South Korea.

CR10049 targets a group of kinases with a crucial role in the OA disease. Their inhibition resulted in a strong reduction of inflammation leading to a significant improvement in pain behaviour as well as in the overall joint structure.

Presentation Details

Title: CR10049, the first OA-targeted kinase inhibitor, as a treatment for the inflammatory OA phenotype.

Abstract and Poster Number: 647

Presenting Author: Tiziana Piepoli

Presentation Session Date and Time: Friday, April 25, and Saturday, April 26, 2025, 3:30 – 4:15 pm PDT

The abstract has been published in the April issue of [Osteoarthritis and Cartilage Volume 33, Supplement S449, 2025](#).

CR10049 (targeted kinase inhibitor for the inflammatory OA phenotype)

CR10049 is the lead of a series of small molecules with potent activity on undisclosed selected kinases that play a role in both OA pain (symptom-modifying) and inflammatory joint degeneration (structure-modifying). One such drug would be a major breakthrough in the treatment of inflammatory OA.

Rottapharm Biotech

Rottapharm Biotech is a research company dedicated to the discovery and development of innovative drugs. It is located in Monza (Italy). The company

expertise in research and development includes medicinal/computational chemistry for small molecules, development of biologics and advanced therapies, new targets validation, pharmacological and pharmacokinetic characterization of new drug candidates, original formulations, and design of innovative clinical trials. The company strategy is to develop its own pipeline independently and then seek partnerships with pharmaceutical companies, as well as investing in alliances on innovative projects of other biotech companies or university spin-offs.

Contact

Federica Girolami, Business Development Director

Tel. +39 346 4131428

federica.girolami@rottapharmbiotech.com